|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
JPH0742304B2
(ja)
|
1986-12-05 |
1995-05-10 |
財団法人微生物化学研究会 |
新規なアンスラサイクリン誘導体およびその製造法
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
DE3712350A1
(de)
|
1987-04-11 |
1988-10-20 |
Behringwerke Ag |
Semisynthetische rhodomycine, verfahren zu ihrer herstellung und ihre verwendung als zytostatika
|
|
EP0335369A3
(en)
|
1988-03-29 |
1990-03-28 |
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai |
New anthracycline derivatives and processes for the preparation of the same
|
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
|
ES2096590T3
(es)
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
Reactivos biespecificos para la terapia del sida.
|
|
HU9203720D0
(en)
|
1990-06-11 |
1993-03-29 |
Iaf Biochem Int |
Method for producing heterocyclic derivatives of anthracyclinole and anthracycline
|
|
WO1992000373A1
(en)
|
1990-06-29 |
1992-01-09 |
Biosource Genetics Corporation |
Melanin production by transformed microorganisms
|
|
MY106399A
(en)
|
1990-07-24 |
1995-05-30 |
Pfizer |
Cephalosporins and homologeus, preparation and pharmaceutical composition
|
|
US5192880A
(en)
|
1990-11-13 |
1993-03-09 |
Nec Corporation |
High-speed emitter coupled logic circuit with large current driving capability
|
|
KR100211417B1
(ko)
|
1990-11-30 |
1999-10-01 |
유충식 |
L-탈로피라노시드 유도체 및 그의 제조방법
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
NZ241606A
(en)
|
1991-02-28 |
1994-08-26 |
Iaf Biochem Int |
Heteroanthracycline antitumor analogs, preparation and pharmaceutical compositions thereof; intermediates therefor
|
|
JP3025056B2
(ja)
|
1991-03-12 |
2000-03-27 |
財団法人微生物化学研究会 |
２，６−ジデオキシ−２−フルオロ−ｌ−タロピラノース誘導体の製造法
|
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
|
JPH04290891A
(ja)
|
1991-03-19 |
1992-10-15 |
Yasumitsu Tamura |
新規なアンスラサイクリン系化合物
|
|
DE4111971C1
(enExample)
|
1991-04-12 |
1992-03-12 |
Wolf-Dieter Dr. 7803 Gundelfingen De Fessner |
|
|
US5552534A
(en)
|
1991-08-22 |
1996-09-03 |
The Trustees Of The University Of Pennsylvania |
Non-Peptide peptidomimetics
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
FI941732L
(fi)
|
1991-10-15 |
1994-06-14 |
Scripps Research Inst |
Fukosyloitujen hiilihydraattien valmistaminen sokerinukleotidien entsymaattisella fukosylointisyteesillä ja GDP-fukoosin in situ regenerointi
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
WO1993010260A1
(en)
|
1991-11-21 |
1993-05-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
US5278311A
(en)
|
1992-06-05 |
1994-01-11 |
E. R. Squibb & Sons, Inc. |
Nonionic radiographic contrast agents
|
|
US5736523A
(en)
|
1992-11-09 |
1998-04-07 |
Biochem Pharma Inc. |
Antineoplastic heteronapthoquinones
|
|
DK76193D0
(da)
|
1993-06-25 |
1993-06-25 |
Astra Ab |
Kulhydratderivater
|
|
US5670315A
(en)
|
1993-09-13 |
1997-09-23 |
Canon Kabushiki Kaisha |
Nucleic acid determination employing pyryilium dye
|
|
GB9418260D0
(en)
|
1994-09-09 |
1994-10-26 |
Erba Carlo Spa |
Anthracycline derivatives
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
JPH08286368A
(ja)
|
1995-04-14 |
1996-11-01 |
Toyo Ink Mfg Co Ltd |
着色画像形成材料およびそれを用いた着色画像形成媒体と着色画像形成方法
|
|
US6245347B1
(en)
|
1995-07-28 |
2001-06-12 |
Zars, Inc. |
Methods and apparatus for improved administration of pharmaceutically active compounds
|
|
EP0761678B1
(en)
|
1995-09-08 |
1999-03-31 |
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai |
Fluorine-containing anthracycline derivatives having hydroxyl group(s) mono- or di-o-aminoalkanoylated in the sugar moiety thereof
|
|
DE19541260A1
(de)
|
1995-11-06 |
1997-05-07 |
Lohmann Therapie Syst Lts |
Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US6512010B1
(en)
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
|
PL182601B1
(pl)
|
1996-07-17 |
2002-02-28 |
Waldpharm Sp Z Oo |
Sposób otrzymywania antybiotyków antracyklinowych
|
|
DE19640969A1
(de)
|
1996-10-04 |
1998-04-16 |
Bayer Ag |
20-0-verknüpfte Glycokonjugate von Camptothecin
|
|
US5770407A
(en)
|
1996-12-10 |
1998-06-23 |
The Scripps Research Institute |
Process for preparing nucleotide inhibitors of glycosyltransferases
|
|
FR2764304B1
(fr)
|
1997-06-06 |
1999-07-16 |
Rhone Poulenc Rorer Sa |
Nouvelle classe d'agents transfectants cationiques des acides nucleiques
|
|
JPH1135593A
(ja)
|
1997-07-18 |
1999-02-09 |
Daikin Ind Ltd |
２−フルオロフコシル−ｎ−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法
|
|
US6248864B1
(en)
|
1997-12-31 |
2001-06-19 |
Adherex Technologies, Inc. |
Compounds and methods and modulating tissue permeability
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
US6312717B1
(en)
|
1998-07-07 |
2001-11-06 |
Bristol-Myers Squibb Company |
Method for treatment of anxiety and depression
|
|
SE9802864D0
(sv)
|
1998-08-27 |
1998-08-27 |
Pharmacia & Upjohn Ab |
Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
|
|
NZ513144A
(en)
|
1999-02-05 |
2003-05-30 |
Samsung Electronics Co Ltd |
Image texture retrieving method and apparatus thereof
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
US6544548B1
(en)
|
1999-09-13 |
2003-04-08 |
Keraplast Technologies, Ltd. |
Keratin-based powders and hydrogel for pharmaceutical applications
|
|
US20080050809A1
(en)
|
1999-09-28 |
2008-02-28 |
Alejandro Abuin |
Novel human kinases and polynucleotides encoding the same
|
|
US20040219521A1
(en)
|
2000-01-21 |
2004-11-04 |
Tang Y. Tom |
Novel nucleic acids and polypeptides
|
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
|
US6670330B1
(en)
|
2000-05-01 |
2003-12-30 |
Theodore J. Lampidis |
Cancer chemotherapy with 2-deoxy-D-glucose
|
|
US6696081B2
(en)
|
2000-06-09 |
2004-02-24 |
Duke University |
Carbohydrate based lipid compositions and supramolecular structures comprising same
|
|
EP1296992B1
(de)
|
2000-06-26 |
2008-04-23 |
Basf Se |
Phosphacyclohexane und ihre verwendung in der hydroformylierung von olefinen
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
AU2002366951A1
(en)
|
2001-12-10 |
2003-07-09 |
Nuvelo,Inc. |
Novel nucleic acids and polypeptides
|
|
WO2003068943A2
(en)
|
2002-02-13 |
2003-08-21 |
Incyte Corporation |
Secreted proteins
|
|
EP1575480A4
(en)
|
2002-02-22 |
2008-08-06 |
Genentech Inc |
COMPOSITIONS AND METHODS OF TREATING IMMUNE-INFLAMMATORY DISEASES
|
|
US7193069B2
(en)
|
2002-03-22 |
2007-03-20 |
Research Association For Biotechnology |
Full-length cDNA
|
|
AUPS247502A0
(en)
|
2002-05-22 |
2002-06-13 |
Griffith University |
An antimicrobial agent
|
|
JP5401001B2
(ja)
|
2002-09-11 |
2014-01-29 |
ジェネンテック， インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
|
EP1578373A4
(en)
|
2002-09-11 |
2007-10-24 |
Genentech Inc |
NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
|
|
WO2004032845A2
(en)
|
2002-10-07 |
2004-04-22 |
Encore Pharmaceuticals, Inc. |
R-nsaid esters and their use
|
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス， インコーポレイテッド |
抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
|
EP1613261A4
(en)
|
2003-04-09 |
2011-01-26 |
Novo Nordisk As |
INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
|
|
CA2528152A1
(en)
|
2003-06-03 |
2005-01-06 |
The Regents Of The University Of California |
Compositions and methods for treatment of disease with acetylated disaccharides
|
|
FR2858235B1
(fr)
|
2003-07-31 |
2006-02-17 |
Lab Francais Du Fractionnement |
Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
|
|
EP1687291A4
(en)
|
2003-11-17 |
2009-01-07 |
Aromagen Corp |
NEW CYCLIC OXYGENIZED COMPOUNDS OF COOLING AS WELL AS FRAGRANCE AND TASTE PROPERTIES, AND APPLICATIONS THEREFOR
|
|
CN1906203A
(zh)
|
2003-12-23 |
2007-01-31 |
普罗吉恩工业有限公司 |
葡糖胺基聚糖(gag)模拟物
|
|
PL369253A1
(pl)
|
2004-07-23 |
2006-02-06 |
Zakład Badawczo-Produkcyjny SYNTEX Sp.z o.o. |
Sposób otrzymywania złożonych 2-deoksy-2-jodopiranozydów o wysokiej czystości, szczególnie Annamycyny o czystości farmaceutycznej
|
|
MX2007000998A
(es)
|
2004-07-30 |
2007-07-11 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
|
|
JP2008516938A
(ja)
|
2004-10-15 |
2008-05-22 |
アストラゼネカ アクチボラグ |
置換アデニンとその使用
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
EP1891107B1
(en)
|
2005-05-12 |
2011-07-06 |
ZymoGenetics, Inc. |
Compositions and methods for modulating immune responses
|
|
US8303955B2
(en)
|
2005-05-26 |
2012-11-06 |
Seattle Genetics, Inc. |
Humanized anti-CD40 antibodies and their methods of use
|
|
EP1963534A2
(en)
|
2005-12-19 |
2008-09-03 |
Genizon Biosciences Inc. |
Genemap of the human gene associated with crohn's disease
|
|
WO2007100728A2
(en)
|
2006-02-24 |
2007-09-07 |
University Of Miami |
Mannose derivatives for killing tumor cells
|
|
BRPI0708273A2
(pt)
|
2006-02-24 |
2011-05-24 |
Univ Texas |
uso de compostos de hexoses
|
|
US20100075377A1
(en)
|
2006-04-13 |
2010-03-25 |
West James W |
Tetramerizing polypeptides and methods of use
|
|
WO2007124283A2
(en)
|
2006-04-13 |
2007-11-01 |
Zymogenetics, Inc. |
Tetramerizing polypeptides and methods of use
|
|
US9149489B2
(en)
|
2006-04-27 |
2015-10-06 |
Board Of Regents, University Of Texas System |
Inhibitors of glycolysis useful in the treatment of brain tumors
|
|
AU2007284651B2
(en)
|
2006-08-09 |
2014-03-20 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
|
DE102006053637B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
DE102006053635B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
PT2099823E
(pt)
|
2006-12-01 |
2014-12-22 |
Seattle Genetics Inc |
Agentes de ligação ao alvo variantes e suas utilizações
|
|
WO2008131024A1
(en)
|
2007-04-17 |
2008-10-30 |
Board Of Regents, The University Of Texas System |
Iodo-hexose compounds useful to treat cancer
|
|
GB0714514D0
(en)
*
|
2007-07-26 |
2007-09-05 |
Univ City |
Computer system
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
EP3124497B1
(en)
|
2007-09-14 |
2020-04-15 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
CN102099055A
(zh)
|
2007-10-04 |
2011-06-15 |
津莫吉尼蒂克斯公司 |
B7家族成员zB7H6及相关的组合物和方法
|
|
US8293720B2
(en)
|
2007-12-20 |
2012-10-23 |
Dogwood Pharmaceuticals, Inc. |
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
|
|
NZ587143A
(en)
|
2008-02-12 |
2011-07-29 |
Dow Agrosciences Llc |
Pesticidal compositions
|
|
JP5260093B2
(ja)
|
2008-03-10 |
2013-08-14 |
クラレノリタケデンタル株式会社 |
重合性単量体、重合性組成物及び歯科用材料
|
|
EP3231804B1
(en)
|
2008-03-21 |
2021-03-03 |
The General Hospital Corporation |
Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
|
|
CN101555262A
(zh)
|
2008-04-08 |
2009-10-14 |
中国科学院生态环境研究中心 |
六水合三氯化铁(FeCl3·6H2O)选择性脱除糖类化合物异头碳酰基的方法
|
|
SG10202112838YA
(en)
|
2008-04-09 |
2021-12-30 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
|
WO2009135181A2
(en)
|
2008-05-02 |
2009-11-05 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
WO2009143515A2
(en)
|
2008-05-23 |
2009-11-26 |
University Of Miami |
Treatment using continuous low dose application of sugar analogs
|
|
KR20110116220A
(ko)
|
2009-02-11 |
2011-10-25 |
다우 아그로사이언시즈 엘엘씨 |
살충 조성물
|
|
US20120064100A1
(en)
|
2009-03-18 |
2012-03-15 |
Simon Barry |
Biomarkers and uses thereof
|
|
WO2010111713A2
(en)
|
2009-03-27 |
2010-09-30 |
Zacharon Pharmaceuticals, Inc. |
N-linked glycan biosynthesis modulators
|
|
AU2010240569A1
(en)
|
2009-04-20 |
2011-10-20 |
Pfizer Inc. |
Control of protein glycosylation and compositions and methods relating thereto
|
|
US9624255B2
(en)
|
2009-08-11 |
2017-04-18 |
Arizona Board Of Regents |
Carbohydrate-mediated tumor targeting
|
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
|
EP2566876A4
(en)
|
2010-05-06 |
2014-01-08 |
Univ Fraser Simon |
METHOD AND COMPOUNDS FOR INHIBITING GLYCOSYL TRANSFERASES
|
|
US8822642B2
(en)
|
2010-06-09 |
2014-09-02 |
Zymogenetics, Inc. |
Dimeric fusion proteins and related compositions and methods
|
|
KR102318383B1
(ko)
|
2010-07-16 |
2021-10-27 |
아디맵 엘엘씨 |
항체 라이브러리
|
|
RU2625768C2
(ru)
|
2010-08-05 |
2017-07-18 |
Сиэтл Дженетикс, Инк. |
Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы
|
|
BR112013002979A2
(pt)
|
2010-08-12 |
2016-06-07 |
Novozymes Inc |
composição, e, método para degradar ou converter um material celulósico, para produzir um produto de fermentação, e para fermentar um material celulósico.
|
|
TWI410431B
(zh)
|
2010-12-22 |
2013-10-01 |
Ind Tech Res Inst |
齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
|
|
US8923278B2
(en)
|
2011-01-10 |
2014-12-30 |
Vtech Telecommunications Limited |
Peer-to-peer, internet protocol telephone system with system-wide configuration data
|
|
WO2012097052A2
(en)
|
2011-01-11 |
2012-07-19 |
Intertech Bio, Llc |
Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
|
|
US9493452B2
(en)
|
2011-03-24 |
2016-11-15 |
Southern Methodist University |
Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
|
|
EP2714698B1
(en)
|
2011-05-31 |
2016-11-09 |
Merck Patent GmbH |
Compounds containing hydrido-tricyano-borate anions
|
|
CN103687863B9
(zh)
|
2011-07-15 |
2016-07-27 |
默克专利有限公司 |
含有烷基-氰基-硼酸根或烷基-氰基-氟硼酸根阴离子的化合物
|
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
|
CN104411826A
(zh)
|
2012-03-13 |
2015-03-11 |
萨克生物研究学院 |
使用腺病毒和化学二聚体的选择性细胞寻靶
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
AU2013266069B2
(en)
|
2012-05-25 |
2018-03-15 |
Sloan Kettering Institute For Cancer Research |
Methods for treating GI syndrome and graft versus host disease
|
|
EP3202419A1
(en)
|
2012-06-06 |
2017-08-09 |
OncoMed Pharmaceuticals, Inc. |
Pvrig binding agents that modulate the hippo pathway and uses thereof
|
|
EP3508215A3
(en)
|
2012-12-03 |
2019-10-02 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
HK1210964A1
(en)
|
2012-12-04 |
2016-05-13 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
BR112016000853A2
(pt)
|
2013-07-16 |
2017-12-12 |
Genentech Inc |
métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
|
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
|
EP3060581A4
(en)
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
|
US20150132744A1
(en)
|
2013-11-13 |
2015-05-14 |
Oregon Health And Science University |
Methods of detecting cells latently infected with hiv
|
|
WO2015097536A2
(en)
*
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
|
EP3119913B1
(en)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
|
EP3169363A4
(en)
|
2014-07-16 |
2018-02-21 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using tigit inhibitors and anti-cancer agents
|
|
MD4733C1
(ro)
|
2014-08-19 |
2021-07-31 |
Merck Sharp & Dohme Corp |
Anticorpi anti-TIGIT
|
|
BR112017008959A2
(pt)
|
2014-10-29 |
2018-01-16 |
Seattle Genetics, Inc. |
método para tratamento de uma doença.
|
|
WO2016073906A2
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Transforming growth factor-related immunoassays
|
|
US20190119353A1
(en)
|
2014-11-06 |
2019-04-25 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
ES2905615T3
(es)
|
2014-11-20 |
2022-04-11 |
Promega Corp |
Sistemas y métodos para evaluar moduladores de puntos de control inmunitario
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
DK3237446T3
(en)
|
2014-12-22 |
2021-07-26 |
Pd 1 Acquisition Group Llc |
Anti-PD-1-antistoffer
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
JP2018502123A
(ja)
|
2015-01-20 |
2018-01-25 |
イミューンエクサイト， インコーポレイテッド |
癌免疫療法のための組成物及び方法
|
|
US10550173B2
(en)
|
2015-02-19 |
2020-02-04 |
Compugen, Ltd. |
PVRIG polypeptides and methods of treatment
|
|
DK3653221T5
(da)
|
2015-02-19 |
2024-08-26 |
Compugen Ltd |
Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
CN121159719A
(zh)
|
2015-04-17 |
2025-12-19 |
高山免疫科学股份有限公司 |
具有可调的亲和力的免疫调节蛋白
|
|
US11022615B2
(en)
|
2015-05-04 |
2021-06-01 |
University Of Florida Research Foundation, Inc. |
Regulatory T-cells, method for their isolation and uses
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
CA2988119A1
(en)
|
2015-06-03 |
2016-12-08 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
CN108290936B
(zh)
*
|
2015-08-14 |
2022-07-12 |
默沙东公司 |
抗tigit抗体
|
|
WO2017040666A2
(en)
|
2015-08-31 |
2017-03-09 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
WO2017040660A1
(en)
|
2015-08-31 |
2017-03-09 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
EP3344658B1
(en)
|
2015-09-02 |
2022-05-11 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
|
|
CA2997551A1
(en)
|
2015-09-04 |
2017-03-09 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
CN108513576A
(zh)
|
2015-09-14 |
2018-09-07 |
高山免疫科学股份有限公司 |
可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
|
|
EP3349792A1
(en)
|
2015-09-14 |
2018-07-25 |
Compass Therapeutics LLC |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
|
|
PE20181046A1
(es)
|
2015-09-25 |
2018-07-03 |
Genentech Inc |
Anticuerpos anti-tigit y metodos de uso
|
|
PT3356413T
(pt)
|
2015-10-01 |
2022-04-04 |
Potenza Therapeutics Inc |
Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
|
|
JP6981973B2
(ja)
|
2015-10-01 |
2021-12-17 |
ヒート バイオロジクス，インコーポレイテッド |
Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
|
|
PE20181326A1
(es)
|
2015-11-03 |
2018-08-20 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
|
US20180353524A1
(en)
|
2015-12-04 |
2018-12-13 |
Seattle Genetics, Inc. |
Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
|
|
JP7123794B2
(ja)
|
2015-12-09 |
2022-08-23 |
メモリアル スローン ケタリング キャンサー センター |
免疫細胞組成物及びそれを使用する方法
|
|
CA3015619A1
(en)
|
2016-03-01 |
2017-09-08 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human poliovirus receptor (pvr)
|
|
US10537633B2
(en)
|
2016-03-04 |
2020-01-21 |
Jn Biosciences Llc |
Antibodies to TIGIT
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
MX2018012472A
(es)
|
2016-04-15 |
2019-08-12 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
WO2017193059A1
(en)
|
2016-05-06 |
2017-11-09 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
EP4092045A1
(en)
|
2016-05-16 |
2022-11-23 |
Checkmab S.R.L. |
Markers selectively deregulated in tumor-infiltrating regulatory t cells
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
WO2018022946A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
IL317989A
(en)
|
2016-08-17 |
2025-02-01 |
Compugen Ltd |
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
|
|
CN109863242A
(zh)
|
2016-08-30 |
2019-06-07 |
纪念斯隆-凯特林癌症中心 |
用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法
|
|
WO2018041120A1
(en)
|
2016-08-31 |
2018-03-08 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric tigit
|
|
CN116492457A
(zh)
|
2016-09-10 |
2023-07-28 |
耶达研究与开发有限公司 |
降低全身调节性t细胞水平或活性以治疗中枢神经系统的疾病和损伤
|
|
EP3293271A1
(en)
|
2016-09-12 |
2018-03-14 |
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin |
Marker and target as a diagnostic variable and target for therapy of metastatic cancer
|
|
US20190225701A1
(en)
|
2016-09-26 |
2019-07-25 |
The Brigham And Women's Hospital, Inc. |
Regulators of b cell-mediated immunosuppression
|
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
|
EP3589313A4
(en)
*
|
2017-02-28 |
2021-05-19 |
Seagen Inc. |
ANTI-TIGITE ANTIBODY
|
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|